Literature DB >> 15661269

Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome.

Florian Länger1, Jens Dingemann, Hans Kreipe, Ulrich Lehmann.   

Abstract

Analyzing bone marrow trephines from (myelodysplastic syndrome) MDS patients we show for the first time strong over-expression of the DNA methyltransferases 1, and 3A (and 3B to a much lesser extent) in the myelodysplastic syndrome FAB subtypes refractory anaemia (RA) and refractory anaemia with excess of blasts (RAEB). The increase in mRNA expression was much less pronounced in refractory anaemia with ringed sideroblasts (RARS). Classification according to the new WHO guidelines revealed distinct differences between RCMD and RARS. This elevated mRNA expression most probably contributes to the frequently found aberrant hypermethylation in MDS and might explain the promising clinical response of MDS patients treated with DNMT inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661269     DOI: 10.1016/j.leukres.2004.08.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  16 in total

Review 1.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

Review 2.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

3.  DNA methyltransferase expression differs with proliferation in childhood acute lymphoblastic leukemia.

Authors:  Derya Beyza Sayin; Emin Kürekçi; Halil Gürhan Karabulut; Ustün Ezer; Isik Bökesoy
Journal:  Mol Biol Rep       Date:  2009-09-10       Impact factor: 2.316

4.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

Authors:  Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

5.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

Review 6.  Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Giuseppe Leone; Francesco D'Alò; Giuseppe Zardo; Maria Teresa Voso; Clara Nervi
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 7.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

8.  5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1.

Authors:  A Y Maslov; M Lee; M Gundry; S Gravina; N Strogonova; C Tazearslan; A Bendebury; Y Suh; J Vijg
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

9.  Improved methodology for assessment of mRNA levels in blood of patients with FMR1 related disorders.

Authors:  David E Godler; Danuta Z Loesch; Richard Huggins; Lavinia Gordon; Howard R Slater; Freya Gehling; Trent Burgess; K H Andy Choo
Journal:  BMC Clin Pathol       Date:  2009-06-09

Review 10.  Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.

Authors:  Miao Zhang; Jia-Yi Zhang; Ming-Qian Sun; Peng Lu; Jian-Xun Liu
Journal:  Chin J Integr Med       Date:  2020-05-16       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.